AstraZeneca Pharma Q4 FY26 Results Preview & Outlook
AstraZeneca Pharma India latest news:
Updated: 25 Mar 2026 • 4:28 pm
Posted by:
AstraZeneca Pharma India Q4 Results 2026 Preview
- AstraZeneca Pharma India Q4 FY26 revenue is expected to be around Stable Growth Expected, representing a 10-14% YoY increase compared to the same quarter last year.
- Profit After Tax, or PAT, is projected to rise 12-17% YoY.
- EBITDA to rise 14%.
- AstraZeneca Pharma India is expected to show Stable Growth Expected in its revenue.
Click and Sign Up to Get Live Updates on Q4 Results
AstraZeneca Pharma India Share Performance
- Over the past six months, AstraZeneca Pharma India share price has Up by 14-20% to 8401.5.
- Moreover, over the past year, the stock has Up by 26%
- Despite this weak short-term performance, AstraZeneca Pharma India stock has delivered a financially sound 210% return over the past 5 years.
- As of today, 25-03-2026, the AstraZeneca Pharma India share price is trading at 8401.5 per share.
Key Factors to Watch for AstraZeneca Pharma India Q4 Results FY26
- Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
- Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
- Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
- Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
- Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.
Visit Univest app or website to check more AstraZeneca Pharma India latest news to make an informed investment decision.
About AstraZeneca Pharma India
AstraZeneca Pharma India develops pharmaceutical products focusing on oncology, cardiovascular, and respiratory therapies. The company benefits from strong parent support and growing healthcare demand.
Visit Univest app or website to check more AstraZeneca Pharma India latest news to make an informed investment decision.
Final Thoughts
AstraZeneca Pharma India is gear up to announce its Q4 FY26 results. Analysts expect 10-14% revenue growth, a 12-17% rise in PAT, and a 14% rise in EBITDA. AstraZeneca Pharma India focuses on revenue growth from order execution, margin improvement, a strong order book, and management.
Stay informed with Univest blogs to get real-time updates on AstraZeneca Pharma India Q4 results FY26.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Arkade Developers Q4 Results 2026 Preview & Earnings
Arisinfra Solutions Q4 Results 2026 Preview & Earnings
Archidply Industries Q4 results preview with revenue outlook and earnings estimates.
Aqylon Nexus Q4 Results 2026 Preview & Earnings
Apollo Pipes Q4 Results 2026 Preview, Earnings & Demand Outlook
Recent Articles
Tata Consumer Products Shares Jump 7% After Q2 Results: Is This Tata Group Stock a Buy Now? Elara Target, Price Hikes, Valuation and Risks
27 October 2026
Acutaas Chemicals Shares Jump 13% to a Record High After Q2 Profit Rises 71%, Up About 580% in 5 Years: Guidance, Valuation and Risks
27 October 2026
Amazon Stock: Morgan Stanley and UBS Raise Price Targets Ahead of Q3 Results on 29 October, but What Do AWS Margins, Capex and Risks Say?
27 October 2026
Nifty FMCG Index Is Down 22% in 2026: Is Diwali a Buying Opportunity? Valuation, Margin Pressure, Technical Levels and Stocks to Watch
27 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Tata Consumer Products Shares Jump 7% After Q2 Results: Is This Tata Group Stock a Buy Now? Elara Target, Price Hikes, Valuation and Risks
Acutaas Chemicals Shares Jump 13% to a Record High After Q2 Profit Rises 71%, Up About 580% in 5 Years: Guidance, Valuation and Risks
Amazon Stock: Morgan Stanley and UBS Raise Price Targets Ahead of Q3 Results on 29 October, but What Do AWS Margins, Capex and Risks Say?
Nifty FMCG Index Is Down 22% in 2026: Is Diwali a Buying Opportunity? Valuation, Margin Pressure, Technical Levels and Stocks to Watch
Fujiyama Power Systems Shares: Motilal Oswal Sees 36% More Upside With a Rs 500 Target, but Is This Rooftop Solar Stock Still a Buy? Q1 Numbers, Valuation and Risks
Popular this week
Jio Financial Services Share Price Decoded: Reliance Stock Performance Amid Jio Platforms Listing Buzz, Q2 Results, Outlook and Key Levels
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times